文献速递心脏核医学

疑似转甲状腺素蛋白心脏淀粉样变性中99mTc-HMDP心肌摄取SPECT-CT定量的重测再现性

Test-retest reproducibility of myocardial 99mTc-HMDP uptake quantification by SPECT-CT in suspected transthyretin cardiac amyloidosis.
PubMed 文献 · J Nucl Cardiol · 2025-06-13

本研究纳入20例疑似转甲状腺素蛋白相关心脏淀粉样变性(ATTR-CA)患者,间隔一周重复进行平面骨亲和示踪剂心脏闪烁显像和胸部SPECT-CT(2020年10月至2022年12月;临床试验NCT04535349),评估心肌99mTc-HMDP摄取定量的重测、观察者内和观察者间再现性。观察者内和观察者间再现性极好(CCC≥.99);重测再现性SUVmean为CCC .79、SUVmax为CCC .81、%ID为CCC .88、CAA为CCC .93,ICC为.80-.97。结论认为骨亲和示踪剂心脏SPECT-CT在疑似ATTR-CA中定量心肌淀粉样负荷具有极好再现性,%ID和CAA尤其适用于未来纵向研究。

要点

  • 20例疑似ATTR-CA患者间隔一周重复SPECT-CT,观察者内和观察者间CCC≥.99。
  • 重测CCC:SUVmean .79、SUVmax .81、%ID .88、CAA .93。
  • 所有参数与Perugini评分相关,重测ICC为.80-.97。

核心结论

  • 骨亲和示踪剂心脏SPECT-CT在疑似ATTR-CA中定量心肌淀粉样负荷具有极好再现性。
  • %ID和CAA尤其适用于未来纵向研究。

研究设计与样本

  • 20例疑似ATTR-CA患者间隔一周重复进行平面骨亲和示踪剂心脏闪烁显像和胸部SPECT-CT(2020年10月至2022年12月;临床试验NCT04535349)。
  • 平面采集评估Perugini评分;SPECT图像采用CT心脏轮廓勾画和衰减校正定量心肌99mTc-HMDP摄取。
  • 评估指标包括SUVmax、SUVmean、注射剂量百分比(%ID)和心脏淀粉样活性(CAA)。
  • 采用Lin一致性相关系数(CCC)评估一致性;采用平均绝对差、变异系数和组内相关系数(ICC)评估重测再现性。

主要发现

  • 观察者内和观察者间再现性对所有指标均极好(CCC≥.99)。
  • 重测再现性:SUVmean为CCC .79(高度一致),SUVmax为CCC .81、%ID为CCC .88、CAA为CCC .93(几乎完美一致)。
  • 所有参数与Perugini评分相关。
  • 重测信度各指标ICC为.80-.97。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Diagnosing transthyretin-related cardiac amyloidosis (ATTR-CA) relies on excluding plasma cell dyscrasia and performing bone-avid tracer cardiac scintigraphy. However, visual assessment of cardiac uptake has limitations in evaluating amyloid burden. Whole-body single-photon emission computed tomography-computed tomography (SPECT-CT) may overcome these limitations by enabling quantitative assessment, but data on test-retest reproducibility are lacking. OBJECTIVES: This study aimed to evaluate the test-retest, intraobserver and interobserver reproducibility of cardiac amyloid quantification in suspected ATTR-CA using whole-body cadmium zinc telluride SPECT-CT. METHODS: Twenty patients with suspected ATTR-CA underwent repeated planar bone-avid tracer cardiac scintigraphy and thoracic SPECT-CT one week apart (October 2020-December 2022; Clinical Trial: NCT04535349). The Perugini score was assessed using planar acquisition. Cardiac 99mTc-HMDP uptake was quantified on SPECT images with CT-based cardiac contouring and attenuation correction. The evaluated metrics included maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), percentage of injected dose (%ID), and cardiac amyloid activity (CAA). Concordance was evaluated by Lin's concordance correlation coefficient (CCC). Test-retest reproducibility was assessed using the mean absolute difference, coefficient of variation, and intraclass correlation coefficient (ICC). RESULTS: Intraobserver and interobserver reproducibility was excellent for all metrics (CCC ≥.99). Test-retest reproducibility demonstrated substantial agreement for SUVmean (CCC: .79) and almost perfect agreement for SUVmax (CCC: .81), %ID (CCC: .88), and CAA (CCC: .93). All parameters correlated with the Perugini score. Test-retest reliability was high across metrics, with ICC values of .80-.97. CONCLUSIONS: Bone-avid tracer cardiac SPECT-CT shows excellent reproducibility for quantifying cardiac amyloid burden in suspected ATTR-CA, with %ID and CAA being especially reliable for future longitudinal studies. CLINICAL TRIAL REGISTRATION: NCT04535349.

来源:J Nucl Cardiol,查看原文。版权归原作者所有。

引用

  1. Legallois D, Turcan L, Agostini D, et al. Test-retest reproducibility of myocardial 99mTc-HMDP uptake quantification by SPECT-CT in suspected transthyretin cardiac amyloidosis. J Nucl Cardiol. 2025. PMID: 40518108. doi:10.1016/j.nuclcard.2025.102273

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。